In February 2024, Iovance received FDA approval for Amtagvi, its melanoma cell therapy treatment. The treatment works by rejuvenating and multiplying a patient’s tumor-infiltrating lymphocytes (TIL) ...

Iovance stock drops 90% despite historic approval for Amtagvi. Click here for a full investment analysis of IOVA stock.

When a stock is in a freefall, there's usually a justifiable reason for the decline. But for investors with a high risk ...

Iovance’s Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy ...

but Iovance does have the option to purchase an adjacent lot. In February 2024, the San Carlos, California-based company received Food and Drug Administration approval for its melanoma cell ...

Cancer immunotherapy remains a focus of innovation across the industry, with notable 2024 wins Iovance’s and ... the August 2024 Food and Drug Administration (FDA) approval of Neffy, the first ...

Iovance could have a bright future ahead as the Food and Drug Administration (FDA) approved Amtagvi last year, as a treatment for unresectable or metastatic melanoma. Analysts expect it to ...

The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are ...